医药行业24Q2公募基金持仓分析

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [1][21]. Core Insights - As of Q2 2024, the proportion of pharmaceutical stocks in all public fund heavy holdings decreased slightly to 9.41%, down by 0.91 percentage points from Q1 2024 [4]. - The total market value of pharmaceutical stocks held by public funds dropped from 281 billion to 242.7 billion, representing a decline of 14% from Q1 2024 to Q2 2024 [10]. - The top five segments by market value in Q2 2024 were: Medical Devices (63.6 billion, 26%), Chemical Preparations (60.3 billion, 25%), Traditional Chinese Medicine (27.1 billion, 11%), Medical R&D Outsourcing (26.8 billion, 11%), and Medical Consumables (14.8 billion, 6%) [7]. Summary by Sections 2024Q2 Pharmaceutical Stock Holdings Ratio - The pharmaceutical stock holdings ratio among public funds slightly decreased to 9.41% in Q2 2024 [4]. 2024Q2 Pharmaceutical Subsector Public Fund Holdings Market Value - The market value of pharmaceutical stocks held by public funds saw a general decline, with specific segments experiencing both increases and decreases in market value [10]. - The segments that saw an increase included Raw Materials (+2 billion), Blood Products (+1.1 billion), Pharmaceutical Distribution (+0.3 billion), and Medical Devices (+0.03 billion) [10]. 2024Q2 Public Fund Heavy Holdings - The top five public fund heavy holdings by number of funds were: Mindray Medical (512 funds), Heng Rui Medicine (385 funds), Kelun Pharmaceutical (173 funds), WuXi AppTec (111 funds), and Yuyue Medical (103 funds) [13]. - The top five public fund heavy holdings by market value were: Mindray Medical (41.4 billion), Heng Rui Medicine (25.9 billion), WuXi AppTec (12.3 billion), Aier Eye Hospital (7.6 billion), and Kelun Pharmaceutical (7.5 billion) [15].